A double-masked, sham-controlled trial of rose bengal photodynamic therapy for the treatment of fungal and acanthameoba keratitis: Rose Bengal Electromagnetic Activation with Green Light for Infection Reduction (REAGIR) Study.
| Autor: | Prajna V; Aravind Eye Care System., Prajna L; Aravind Eye Hospital., Sharma S; Aravind Eye Hospital., de Freitas D; Federal University of Sao Paulo: Universidade Federal de Sao Paulo., Höfling-Lima AL; Federal University of Sao Paulo: Universidade Federal de Sao Paulo., Varnado N; Stanford University School of Medicine., Abdelrahman S; FI Proctor Foundation., Cavallino V; FI Proctor Foundation., Arnold B; FI Proctor Foundation., Lietman T; FI Proctor Foundation., Rose-Nussbaumer J; Stanford University School of Medicine. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Research square [Res Sq] 2024 Jul 02. Date of Electronic Publication: 2024 Jul 02. |
| DOI: | 10.21203/rs.3.rs-4165312/v1 |
| Abstrakt: | Background: Infectious keratitis secondary to fungus or acanthamoeba often has a poor outcome despite receiving the best available medical therapy. In vitro Rose Bengal Photodynamic therapy (RB-PDT) appears to be effective against fungal and acanthamoeba isolates. 22,23 In one published series RB-PDT reduced the need for therapeutic penetrating keratoplasty in severe bacterial, fungal, and acanthameoba keratitis not responsive to medical therapy. Methods: This international, randomized, sham and placebo controlled 2-arm clinical trial, randomizes patients with smear positive fungal and acanthameoba and smear negative corneal ulcers in a 1:1 fashion to one of two treatment arms: 1) Topical antimicrobial plus sham RB-PDT or 2) Topical antimicrobial plus RB-PDT. Discussion: We anticipate that RB-PDT will improve best spectacle corrected visual acuity and also reduce complications such as corneal perforation and the need for therapeutic penetrating keratoplasty. This study will comply with the NIH Data Sharing Policy and Policy on the Dissemination of NIH-Funded Clinical Trial Information and the Clinical Trials Registration and Results Information Submission rule. Our results will be disseminated via clinicaltrials.gov website, meetings, and journal publications. Our data will also be available upon reasonable request. Trial Registration: NCT, NCT05110001, Registered November 5, 2021. https://www.clinicaltrials.gov/study/NCT05110001. Competing Interests: Competing Interests There are no conflicts of interest to report. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|